MULTIPLICOM NV - Belgium 
Ranking results:
Past rankings:
| 2012 | |
|---|---|
| Criterium: | Position: |
| Overall Score: | 900-1000 |
| Networking Rank (Reputation): | 800-900 |
| Networking Rank (Reputation): | 800-900 |
Ranking timeline:
Project Participation Performance(2012-01-01 - 2024-12-31 ):
Total Project Funding:
Funding per Partner:
Projects:
Leadership:
Total number of projects: 5
As coordinator: 0
As participant: 4
Sole participant: 1
Coordinator / Participant Ratio: 0*
Summary:
| Total project funding [€]: | Projects [No]: | |||||
|---|---|---|---|---|---|---|
| Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
| 2015 | 50.000 | 0 | 50.000 | 1 | ||
| 2013 | 0 | 16.906.363 | 596.280 | 2 | ||
| 2012 | 0 | 14.618.067 | 666.877 | 2 | ||
Networking:
Partners:
Constancy:
Total number of partners: 67
Partner loyalty:
Frequent Partner: (> 2 projects): 3
Rare Partner: 64
Frequent / Rare Partner Ratio: 0.05
Project overview:
| Start date | Project | acronym | role | funding | partners |
|---|---|---|---|---|---|
| 2015-01-01 | Validation of diagnostic and/or prognostic miRNAs in triple-negative breast cancer | MIRCAB | coordinator | 50.000 | 1 |
| 2013-12-01 | A Phase Ib/II study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor PF-02341066 in KRASMT and KRASWT (with aberrant c-MET) Colorectal Cancer Patients | MERCURIC | participant | 5.999.995 | 13 |
| 2013-02-01 | Biomarker Research Alliance for Diagnosing Heart Disease in the Ageing European Population | BESTAGEING | participant | 10.906.368 | 19 |
| 2012-12-01 | A Europe-wide Strategy to enhance Transplantation of highly sensitized patients on basis of Acceptable HLA Mismatches | EUROSTAM | participant | 2.623.500 | 11 |
| 2012-10-01 | European Consortium for High-Throughput Research in Rare Kidney Diseases | EURENOMICS | participant | 11.994.567 | 28 |